Inflammatory factors are associated with prognosis of non-small cell lung cancer patients receiving immunotherapy: a meta-analysis
Abstract This study aimed to explore the association between inflammation-based prognostic markers and outcomes in non-small cell lung cancer (NSCLC) patients undergoing therapy with immune checkpoint inhibitors (ICIs). We conducted a comprehensive search of the Embase, PubMed, and Cochrane database...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2024-10-01
|
| Series: | Scientific Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.1038/s41598-024-76052-2 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850179856304701440 |
|---|---|
| author | Wenxian Tong Huilin Xu Jindan Tang Nan Zhao Dingjie Zhou Chunzhou Chen Dedong Cao |
| author_facet | Wenxian Tong Huilin Xu Jindan Tang Nan Zhao Dingjie Zhou Chunzhou Chen Dedong Cao |
| author_sort | Wenxian Tong |
| collection | DOAJ |
| description | Abstract This study aimed to explore the association between inflammation-based prognostic markers and outcomes in non-small cell lung cancer (NSCLC) patients undergoing therapy with immune checkpoint inhibitors (ICIs). We conducted a comprehensive search of the Embase, PubMed, and Cochrane databases for studies that reported on the impact of inflammation-based prognostic factors, such as C-reactive protein (CRP), on the prognosis of NSCLC patients treated with ICIs. The primary outcomes of interest were overall survival (OS) and progression-free survival (PFS). Statistical analyses were performed using Stata 14 software, with assessments of publication bias and heterogeneity conducted as necessary. Our meta-analysis included 27 studies encompassing 5,174 patients, evaluating factors such as CRP, the modified Glasgow Prognostic Score (mGPS), and the CRP-albumin ratio (CAR). The analysis revealed that elevated levels of CRP were significantly correlated with both reduced PFS (I2 = 0%, P = 0.72; HR = 1.50, 95%CI: 1.33–1.67, P < 0.01) and shorter OS (I2 = 0%, P = 0.55; HR = 1.90, 95%CI: 1.50–2.30, P < 0.01). Similarly, elevated levels of mGPS values were associated with worse PFS (I2 = 0%, P = 0.75; HR = 1.28, 95%CI: 1.10–1.46, P < 0.05) and OS (I2 = 0%, P = 0.94; HR = 1.56, 95%CI: 1.31–1.81, P < 0.05). However, the relationship between elevated levels of CAR and worse outcomes for PFS (I2 = 59.6%, P = 0.94; HR = 1.42, 95%CI: 0.74–2.11, P > 0.05) and OS (I2 = 45.3%, P = 0.16; HR = 1.41, 95%CI: 0.70–2.13, P > 0.05) was not statistically significant. Our findings suggest that CRP and mGPS may serve as potential prognostic markers in NSCLC patients receiving immunotherapy. Nonetheless, further research with more homogeneous study populations is necessary to valid these observations. |
| format | Article |
| id | doaj-art-50937a8f81d14e27b9f9c67dea4536b3 |
| institution | OA Journals |
| issn | 2045-2322 |
| language | English |
| publishDate | 2024-10-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Scientific Reports |
| spelling | doaj-art-50937a8f81d14e27b9f9c67dea4536b32025-08-20T02:18:24ZengNature PortfolioScientific Reports2045-23222024-10-0114111110.1038/s41598-024-76052-2Inflammatory factors are associated with prognosis of non-small cell lung cancer patients receiving immunotherapy: a meta-analysisWenxian Tong0Huilin Xu1Jindan Tang2Nan Zhao3Dingjie Zhou4Chunzhou Chen5Dedong Cao6Department of Oncology, The Fifth Hospital of WuHanDepartment of Oncology, The Fifth Hospital of WuHanDepartment of Nursing, The Fifth Hospital of WuHanDepartment of Oncology, RenMin Hospital of WuHan UniversityDepartment of Oncology, RenMin Hospital of WuHan UniversityDepartment of General Surgery, The Fifth Hospital of WuHanDepartment of Oncology, RenMin Hospital of WuHan UniversityAbstract This study aimed to explore the association between inflammation-based prognostic markers and outcomes in non-small cell lung cancer (NSCLC) patients undergoing therapy with immune checkpoint inhibitors (ICIs). We conducted a comprehensive search of the Embase, PubMed, and Cochrane databases for studies that reported on the impact of inflammation-based prognostic factors, such as C-reactive protein (CRP), on the prognosis of NSCLC patients treated with ICIs. The primary outcomes of interest were overall survival (OS) and progression-free survival (PFS). Statistical analyses were performed using Stata 14 software, with assessments of publication bias and heterogeneity conducted as necessary. Our meta-analysis included 27 studies encompassing 5,174 patients, evaluating factors such as CRP, the modified Glasgow Prognostic Score (mGPS), and the CRP-albumin ratio (CAR). The analysis revealed that elevated levels of CRP were significantly correlated with both reduced PFS (I2 = 0%, P = 0.72; HR = 1.50, 95%CI: 1.33–1.67, P < 0.01) and shorter OS (I2 = 0%, P = 0.55; HR = 1.90, 95%CI: 1.50–2.30, P < 0.01). Similarly, elevated levels of mGPS values were associated with worse PFS (I2 = 0%, P = 0.75; HR = 1.28, 95%CI: 1.10–1.46, P < 0.05) and OS (I2 = 0%, P = 0.94; HR = 1.56, 95%CI: 1.31–1.81, P < 0.05). However, the relationship between elevated levels of CAR and worse outcomes for PFS (I2 = 59.6%, P = 0.94; HR = 1.42, 95%CI: 0.74–2.11, P > 0.05) and OS (I2 = 45.3%, P = 0.16; HR = 1.41, 95%CI: 0.70–2.13, P > 0.05) was not statistically significant. Our findings suggest that CRP and mGPS may serve as potential prognostic markers in NSCLC patients receiving immunotherapy. Nonetheless, further research with more homogeneous study populations is necessary to valid these observations.https://doi.org/10.1038/s41598-024-76052-2Non-small cell lung cancerC-reactive proteinModified Glasgow prognostic scoreC-reactive protein/Albumin ratioPrognosis |
| spellingShingle | Wenxian Tong Huilin Xu Jindan Tang Nan Zhao Dingjie Zhou Chunzhou Chen Dedong Cao Inflammatory factors are associated with prognosis of non-small cell lung cancer patients receiving immunotherapy: a meta-analysis Scientific Reports Non-small cell lung cancer C-reactive protein Modified Glasgow prognostic score C-reactive protein/Albumin ratio Prognosis |
| title | Inflammatory factors are associated with prognosis of non-small cell lung cancer patients receiving immunotherapy: a meta-analysis |
| title_full | Inflammatory factors are associated with prognosis of non-small cell lung cancer patients receiving immunotherapy: a meta-analysis |
| title_fullStr | Inflammatory factors are associated with prognosis of non-small cell lung cancer patients receiving immunotherapy: a meta-analysis |
| title_full_unstemmed | Inflammatory factors are associated with prognosis of non-small cell lung cancer patients receiving immunotherapy: a meta-analysis |
| title_short | Inflammatory factors are associated with prognosis of non-small cell lung cancer patients receiving immunotherapy: a meta-analysis |
| title_sort | inflammatory factors are associated with prognosis of non small cell lung cancer patients receiving immunotherapy a meta analysis |
| topic | Non-small cell lung cancer C-reactive protein Modified Glasgow prognostic score C-reactive protein/Albumin ratio Prognosis |
| url | https://doi.org/10.1038/s41598-024-76052-2 |
| work_keys_str_mv | AT wenxiantong inflammatoryfactorsareassociatedwithprognosisofnonsmallcelllungcancerpatientsreceivingimmunotherapyametaanalysis AT huilinxu inflammatoryfactorsareassociatedwithprognosisofnonsmallcelllungcancerpatientsreceivingimmunotherapyametaanalysis AT jindantang inflammatoryfactorsareassociatedwithprognosisofnonsmallcelllungcancerpatientsreceivingimmunotherapyametaanalysis AT nanzhao inflammatoryfactorsareassociatedwithprognosisofnonsmallcelllungcancerpatientsreceivingimmunotherapyametaanalysis AT dingjiezhou inflammatoryfactorsareassociatedwithprognosisofnonsmallcelllungcancerpatientsreceivingimmunotherapyametaanalysis AT chunzhouchen inflammatoryfactorsareassociatedwithprognosisofnonsmallcelllungcancerpatientsreceivingimmunotherapyametaanalysis AT dedongcao inflammatoryfactorsareassociatedwithprognosisofnonsmallcelllungcancerpatientsreceivingimmunotherapyametaanalysis |